Clinical Trial Update: Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluating losartan and spironolactone for ICU patients with COVID-19 and acute respiratory distress syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Losartan (losartan)
• Spironolactone (spironolactone)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: COVID-19, ARDS | Phase 2 | Status: TERMINATED